Related Experiment Video
Updated: Sep 13, 2025

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
Delayed Bone Age and Osteoprotegerin Levels in Pediatric Celiac Disease: A Three-Year Case-Control Study
Ruzha Pancheva1, Yoana Dyankova2, Niya Rasheva2
1Department of Hygiene and Epidemiology, Faculty of Public Health, Prof. Dr. Paraskev Stoyanov Medical University, 9000 Varna, Bulgaria.
Insights
Osteoprotegerin (OPG) levels reflect disease activity and growth delay in pediatric celiac disease (CD). However, OPG is not a reliable standalone biomarker for predicting delayed bone age in these children.
Area of Science:
- Pediatric Endocrinology
- Gastroenterology
- Bone Metabolism
Background:
- Celiac disease (CD) negatively impacts bone development in children due to inflammation and malabsorption.
- Osteoprotegerin (OPG), a key regulator of bone remodeling, is a potential biomarker for bone health and inflammation.
- The clinical utility of OPG in pediatric CD requires further investigation.
Purpose of the Study:
- To assess the relationship between OPG levels, growth parameters, and bone age delay in pediatric CD patients.
- To evaluate OPG as a potential biomarker for bone health and disease activity in children with CD.
Main Methods:
- A three-year case-control study involving 146 children (25 newly diagnosed CD, 54 established CD on gluten-free diet, 67 controls).
- Measurements included OPG, osteocalcin, anthropometrics, and radiological bone age assessment.
- Statistical analyses comprised ANOVA, Spearman's correlations, and logistic regression.
Main Results:
- Elevated OPG levels were observed in newly diagnosed CD patients, with a slight, non-significant decrease after gluten-free diet adherence.
- OPG levels showed negative correlations with age and height in CD patients and controls.
- OPG did not significantly predict delayed bone age, though a trend was noted in established CD patients.
Conclusions:
- OPG levels correlate with disease activity and growth delay in pediatric CD.
- OPG is not a suitable standalone biomarker for predicting skeletal maturation or delayed bone age.
- Integrated biomarker panels are recommended for comprehensive bone health monitoring in children with CD.
Abstract:
Introduction: Celiac disease (CD) impairs bone development in children through inflammation and nutrient malabsorption. Osteoprotegerin (OPG), a decoy receptor for RANKL, plays a role in bone remodeling and is increasingly recognized as a potential biomarker of bone metabolism and inflammation. However, its clinical significance in pediatric CD remains unclear. Aim: To evaluate the relationship between OPG levels, growth parameters, and delayed bone age in children with CD, and to assess OPG's potential as a biomarker of bone health and disease activity. Methods: This three-year case-control study included 146 children: 25 with newly diagnosed CD (Group A), 54 with established CD on a gluten-free diet (Group B), and 67 healthy controls (Group C). Participants underwent clinical, anthropometric, and laboratory assessments at baseline and after 6 months (Groups A and B). OPG and osteocalcin were measured, and bone age was assessed radiologically. Statistical analyses included ANOVA, Spearman's correlations, and binomial logistic regression. Results: OPG levels were highest in newly diagnosed children (Group A), showing a non-significant decrease after gluten-free diet initiation. OPG correlated negatively with age and height in CD patients and controls, and positively with hemoglobin and iron in Group B. Logistic regression revealed no significant predictive value of OPG for delayed bone age, although a trend was observed in Group B (p = 0.091). Children in long-term remission exhibited bone maturation patterns similar to healthy peers. Conclusions: OPG levels reflect disease activity and growth delay in pediatric CD but lack predictive power for delayed bone age. While OPG may serve as a secondary marker of bone turnover and inflammatory status, it is not suitable as a standalone biomarker for skeletal maturation. These findings highlight the need for integrative biomarker panels to guide bone health monitoring in children with CD.
More Related Videos
07:23Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification
Published on: December 3, 2016
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...